- Trials with a EudraCT protocol (115)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
115 result(s) found for: Individual participant data.
Displaying page 1 of 6.
EudraCT Number: 2015-000508-24 | Sponsor Protocol Number: 7406 | Start Date*: 2015-06-12 | |||||||||||
Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust | |||||||||||||
Full Title: A Feasibility Study of Bezafibrate in Mitochondrial Myopathy | |||||||||||||
Medical condition: Mitochondrial myopathy due to mt.3243A>G mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002885-15 | Sponsor Protocol Number: AI424-567 | Start Date*: 2020-07-15 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-label, Randomized Crossover Study to Obtain a Preliminary Estimate of the Bioavailability of Atazanavir and Cobicistat When Administered in an Age-appropriate Fixed‑dose Combination Formula... | |||||||||||||
Medical condition: HIV in paediatric population | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000095-15 | Sponsor Protocol Number: OCTO_090 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab With Temozolomide Versus Temozolomide Alone after Surgery and Chemoradiotherapy in Patients with Recently Diagnosed Glioblastoma (IPI-GLIO) | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000447-26 | Sponsor Protocol Number: SPK-8011-301 | Start Date*: 2019-10-23 |
Sponsor Name:Spark Therapeutics, Inc | ||
Full Title: An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A | ||
Medical condition: Hemophilia A | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002372-36 | Sponsor Protocol Number: 2022-16039 | Start Date*: 2024-01-02 |
Sponsor Name:Wageningen Research Stichting | ||
Full Title: The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo controlled N-of-1 trials | ||
Medical condition: Insomnia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003966-38 | Sponsor Protocol Number: CADPT06A12201 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease (EXPLAIN-AD): A randomized, placebo controlled, multicenter platform study to evaluate the efficacy, safety, tolerabili... | |||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000907-29 | Sponsor Protocol Number: SHDE-1 | Start Date*: 2014-08-25 |
Sponsor Name:Hevert-Arzneimittel GmbH & Co. KG | ||
Full Title: Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, paral... | ||
Medical condition: acute, uncomplicated rhinosinusitis | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002177-20 | Sponsor Protocol Number: RLM-MD-02 | Start Date*: 2018-11-06 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis | |||||||||||||
Medical condition: Diabetic Gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000641-23 | Sponsor Protocol Number: CNWL/MC/AFT/01 | Start Date*: 2015-11-24 |
Sponsor Name:Central and North West London NHS Foundation Trust | ||
Full Title: Aggression Following TBI: Effectiveness of Risperidone (AFTER)-a feasibility RCT. | ||
Medical condition: aggression and agitation following on from a traumatic brain injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003138-18 | Sponsor Protocol Number: UCC-Strider | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University College Cork | |||||||||||||
Full Title: STRIDER Ireland: A Randomised Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early‐Onset Intrauterine Growth Restriction | |||||||||||||
Medical condition: Severe early - onset Intrauterine Growth Restriction (IUGR), (also referred to as Fetal growth restriction) diagnosed between 22+0 and 29+6 gestational age. IUGR is defined as an estimated fetal we... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001824-32 | Sponsor Protocol Number: 116174 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002136-16 | Sponsor Protocol Number: RLM-MD-01 | Start Date*: 2019-04-02 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis | |||||||||||||
Medical condition: Diabetic Gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001428-33 | Sponsor Protocol Number: PLN-74809-PSC-203 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Pliant Therapeutics, Inc | |||||||||||||
Full Title: A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis ... | |||||||||||||
Medical condition: Primary sclerosing cholangitis (PSC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) BE (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001015-82 | Sponsor Protocol Number: ALXN1840-WD-302 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric particip... | |||||||||||||
Medical condition: Wilson Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000408-39 | Sponsor Protocol Number: 1487-0003 | Start Date*: 2021-06-02 |
Sponsor Name:SCS Boehringer Ingelheim Comm. V | ||
Full Title: A Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-... | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003405-98 | Sponsor Protocol Number: dexFEMv2 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:ACCORD University of Edinburgh [...] | |||||||||||||
Full Title: Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding | |||||||||||||
Medical condition: Endometrial glucocorticoid deficiency in Heavy Menstrual Bleeding | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000138-20 | Sponsor Protocol Number: AL001-2 | Start Date*: 2019-11-18 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of... | |||||||||||||
Medical condition: Frontotemporal Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000754-97 | Sponsor Protocol Number: OP/2017/6195 | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust | |||||||||||||
Full Title: Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial. | |||||||||||||
Medical condition: Autoimmune non-infectious uveitis (ANIU) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002767-30 | Sponsor Protocol Number: ACT17453 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & developpement | |||||||||||||
Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ... | |||||||||||||
Medical condition: Relapsed/refractory multiple myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000781-15 | Sponsor Protocol Number: COVFATI | Start Date*: 2021-12-14 |
Sponsor Name:Amsterdam UMC VUmc | ||
Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19 | ||
Medical condition: Chronic fatigue after COVID-19 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
